Tesamorelin vs 5-Amino-1MQ
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone PeptidesFat Loss & Metabolic
TesamorelinFat Loss & Metabolic
5-Amino-1MQ- Summary
- Tesamorelin is an FDA-approved synthetic GHRH analog specifically indicated for reduction of excess abdominal (visceral) fat in HIV patients with lipodystrophy. It is the only GHRH peptide with FDA approval for a fat-reduction indication and is studied off-label for metabolic syndrome and cognitive function.
- 5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
- Half-Life
- ~26 minutes
- Estimated 4–8 hours
- Admin Route
- SubQ
- Oral
- Research
- —
- —
- Typical Dose
- 2 mg
- 50–100 mg
- Frequency
- Once daily
- Once to twice daily
- Key Benefits
- FDA-approved for visceral fat reduction in HIV lipodystrophy
- Significant reduction in trunk/visceral fat (average 15–20% in trials)
- Improved triglyceride and lipid profiles
- Potential cognitive benefits and memory improvement
- Preserves lean mass while reducing fat
- Natural pulsatile GH stimulation
- Raises intracellular NAD+ levels
- Directly targets adipose tissue for fat reduction
- Reduces fat cell size and differentiation
- Increases basal metabolic rate
- SIRT1 activation for metabolic regulation
- No stimulant cardiovascular side effects
- Synergistic with intermittent fasting and caloric restriction
- May have anti-aging metabolic benefits
- Side Effects
- Injection site reactions (redness, irritation)
- Arthralgia and joint pain
- Peripheral edema
- Carpal tunnel syndrome
- +2 more
- Generally well-tolerated in available studies
- Mild GI discomfort (rare)
- Limited long-term human data
- Stacks With
- —
- —